Abstract
Currently, there is an increasing need to develop better medical materials with high antithrom—bogenecity. Attempts have, in fact, been made to improve such materials by the following methods; 1) to develop a material compatible with tissue, 2) to coat amaterial with protein, 3) to immobilize an anticoagulant agent on the surface of a material. and 4) to immobilize a fibrinolytic enzyme on the sur face.
Among these methods, the last is intriguing. As already reported, immobilized Urokinase can maintain fibrinolytic ability.
Reported herein are the outcomes of the fundamental and clinical studies on Urokinase treated EVA (ethylene-vinyl acetate eopolymer) tube which is used as intravenous catheter.
The results are as follows:
1) This tube has 7.9±1.8U of urokinase activity per 10cm.
2) The activity was influenced by the procedure of EOG disinfection.
3) This activity decreased after the repeated fibrinolysis test.
4) This tube showed an antitbrombotic action in clinical trial and maintained the almost 10% of initial activity.
